First Manhattan’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

First Manhattan’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-33	Closed	-$1K	–	1514
2022 Q2	$1K	Hold	33	–	–	﹤0.01%	1466
2022 Q1	$1K	Hold	33	–	–	﹤0.01%	1516
2021 Q4	$2K	Hold	33	–	–	﹤0.01%	1468
2021 Q3	$1K	Hold	33	–	–	﹤0.01%	1538
2021 Q2	$1K	Hold	33	–	–	﹤0.01%	1519
2021 Q1	$1K	Hold	33	–	–	﹤0.01%	1433
2020 Q4	$2K	Sell	33 -234	-88%	-$31.9K	﹤0.01%	1271
2020 Q3	$67K	Hold	267	–	–	﹤0.01%	831
2020 Q2	$44K	Hold	267	–	–	﹤0.01%	893
2020 Q1	$18K	Hold	267	–	–	﹤0.01%	1017
2019 Q4	$17K	Hold	267	–	–	﹤0.01%	1073
2019 Q3	$15K	Buy	267 +34	+15%	+$2K	﹤0.01%	1099
2019 Q2	$13K	Hold	233	–	–	﹤0.01%	1150
2019 Q1	$15K	Hold	233	–	–	﹤0.01%	1143
2018 Q4	$12K	Hold	233	–	–	﹤0.01%	1140
2018 Q3	$13K	Hold	233	–	–	﹤0.01%	1187
2018 Q2	$13K	Hold	233	–	–	﹤0.01%	1156
2018 Q1	$11K	Hold	233	–	–	﹤0.01%	1173
2017 Q4	$13K	Hold	233	–	–	﹤0.01%	1207
2017 Q3	$14K	Buy	+233	New	+$15.1K	﹤0.01%	1170

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

First Manhattan's BCLI Position: Q3 2022 in Review

First Manhattan sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2022, closing a stake of 33 shares — an estimated $1K sold.

First Manhattan first reported a position in BCLI in Q3 2017 and held it in 20 quarters. The position peaked at $67K in Q3 2020. 42 funds tracked by Wall St. Rank hold BCLI as of Q3 2022.

First Manhattan reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2022 after selling out during the quarter.
First Manhattan sold 33 BRAINSTORM CELL THERAPUTC shares in Q3 2022, an estimated $1K.
First Manhattan first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 20 quarters.
First Manhattan's BRAINSTORM CELL THERAPUTC position peaked at $67K in Q3 2020.
42 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2022.

Based on First Manhattan's 13F filing for Q3 2022, filed 14 Nov 2022.